• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Royalty Pharma Plc Cl A (NQ: RPRX )

    27.20 +0.10 (+0.37%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Royalty Pharma Plc Cl A

    < Previous 1 2 3 4 5 Next >
    3 Dividend Growth Stocks to Buy Now for a Lifetime of Passive Income
    Buy these stocks now, and the yield on your original investment could reach a double-digit percentage long before you retire. 
    Via The Motley Fool
    Peering Into Royalty Pharma's Recent Short Interest
    Via Benzinga
    2 No-Brainer Dividend Stocks to Buy With $100 in October
    With their high yields and strong underlying businesses, these stocks are hard to pass up. 
    Via The Motley Fool
    2 High-Yield Dividend Stocks Near 52-Week Lows: Are They Buys Now?
    These dividend-paying stocks offer hard-to-find high yields, but that doesn't necessarily make them good stocks to buy now. 
    Via The Motley Fool
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    NASDAQ:RPRX: good value for what you're paying.
    Investors should take notice ofROYALTY PHARMA PLC- CL A (NASDAQ:RPRX)—it offers a great deal for the fundamentals it presents. 
    Via Chartmill
    Looking Into Royalty Pharma's Recent Short Interest
    Via Benzinga
    NASDAQ:RPRX is an undervalued gem with solid fundamentals.
    ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX), an undervalued stock with good fundamentals. 
    Via Chartmill
    3 High-Yield Dividend Stocks Down by More Than 39% to Buy Now and Hold at Least a Decade
    Now could be a great time to scoop up three stocks trading way below their previous peaks. 
    Via The Motley Fool
    2 Unstoppable Dividend Growth Stocks You Can Buy Now With $100
    These dividend payers could more than double their payouts in the decade ahead. 
    Via The Motley Fool
    Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut
    Ascendis Pharma reported lower-than-expected Q2 2024 sales of $38.76 million, missing the consensus estimate of $92.7 million due to a significant adjustment to prior sales estimates. The company... 
    Via Benzinga
    Jim Cramer: This Financial Stock Is A Buy, Core Scientific Is A 'Very Overvalued Situation'
    Jim Cramer discusses Snowflake, Royalty Pharma, Core Scientific and Ally Financial on "Mad Money Lightning Round." 
    Via Benzinga
    RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q2 2024
    RPRX stock results show that Royalty Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Cytokinetics' Wild Ride: Can Investors Forgive The Royalty Pharma Deal?
    CEO Robert Blum says there are key components to the funding arrangement with Royalty Pharma that investors are missing. 
    Via Investor's Business Daily
    Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024
    Selecting strong buy biotech stocks isn’t easy when most of them don’t make money. Here are three possibilities to meet this challenge. 
    Via InvestorPlace
    7 Biotech Stocks to Buy on the Dip: June 2024
    With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. 
    Via InvestorPlace
    Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
    Via Benzinga
    June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge
    Biotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the rest of 2024. 
    Via InvestorPlace
    Why Is Agios Pharmaceuticals Stock Trading Higher On Tuesday?
    Agios Pharmaceuticals sells its 15% royalty rights on U.S. net sales of Servier's vorasidenib to Royalty Pharma for $905 million upon FDA approval. 
    Via Benzinga
    Exposures Product Safety
    Agios Pharmaceuticals Inks $905 Million Deal For Cancer Drug; Shares Poised To Break Out
    The stock is poised to break out of a cup-with-handle base after inking a deal for a cancer drug. 
    Via Investor's Business Daily
    Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe
    Unlock the latest on Royalty Pharma plc & Cytokinetics Inc.'s strategic funding collaboration for aficamten's commercialization and cardiovascular pipeline expansion. 
    Via Benzinga
    7 Dividend Stocks to Buy at a 52-Week Low
    For steady yields, not to mention rebound potential, consider the following seven dividend stocks at a 52-week low. 
    Via InvestorPlace
    RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q1 2024
    RPRX stock results show that Royalty Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment
    Amgen reported quarterly earnings of $3.96 per share which beat the analyst consensus estimate of $3.87 by 2.33%. The company said EPS decreased by 1% due to higher operating and interest expenses... 
    Via Benzinga
    3 Pharma Stocks to Sell in April Before They Crash & Burn
    Discover three pharma stocks to sell in April, facing challenges and signaling potential for significant downside. 
    Via InvestorPlace
    Billionaire Bargain Bin: 3 Stocks the Forbes 400 Loves (That You’ve Never Heard Of)
    These Forbes 400 stocks have wealthy founders who run them with little fanfare or attention but are worth considering for your portfolio. 
    Via InvestorPlace
    April’s Hidden Gems: 3 Overlooked Stocks to Freshen Up Your Portfolio
    Discover three overlooked stocks on Wall Street with the potential for growth and diversification this April. 
    Via InvestorPlace
    The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio
    With a possible rotation away from the technology space, these are the undervalued healthcare stocks to consider. 
    Via InvestorPlace
    For those who appreciate value investing, NASDAQ:RPRX is a compelling option with its solid fundamentals.
    When you look at ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
    Via Chartmill
    Wall Street Thinks These 3 Stocks Are Hidden Gems That Could Soar 43% to 59% Over the Next 12 Months
    Analysts are quite bullish about these beaten-down stocks. 
    Via The Motley Fool
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.